New treatment may improve outcomes for patients with BRCA mutation-associated early breast cancer
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing their DNA (called a PARP inhibitor) has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
Titled Adjuvant Olaparib for Patients with BRCA1 or BRCA2 Mutated Breast Cancer, the paper appears in the June 3 issue of the